Keyphrases
32 Factorial Design
12%
Between-group
12%
Between-group Difference
12%
Body Mass Index
12%
Carotid Intima-media Thickness (cIMT)
50%
Change in Mean
25%
Copenhagen
100%
Denmark
12%
Glycated Hemoglobin A1c
12%
Hemoglobin A1c (HbA1c)
50%
Hypoglycemic Episodes
12%
Insulin
25%
Insulin Analogues
100%
Insulin Dose
37%
Insulin Therapy
100%
Investigator-initiated
12%
Large Reduction
12%
Metformin
100%
Metformin Therapy
100%
Non-severe
25%
Number of Patients
12%
Placebo
100%
Randomized Placebo-controlled Trial
12%
Serious Adverse Events
25%
Subclinical Cardiovascular Disease
12%
Twice Daily
12%
Type 2 Diabetes Mellitus (T2DM)
100%
Type 2 Diabetic Patients
100%
Weight Gain
12%
Nursing and Health Professions
Adverse Event
22%
Antidiabetic Agent
33%
Arterial Wall Thickness
44%
Body Mass
11%
Cardiovascular Disease
11%
Factorial Design
11%
Glycosylated Hemoglobin
11%
Hemoglobin A1c
55%
Insulin Treatment
11%
Metformin
100%
Non Insulin Dependent Diabetes Mellitus
100%
Patient with Type 2 Diabetes
100%
Placebo
100%
Sample Size
11%
Medicine and Dentistry
Adverse Event
22%
Antidiabetic Agent
33%
Body Mass Index
11%
Cardiovascular Disease
11%
Glycated Hemoglobin
11%
Glycon
100%
Hemoglobin A1c
55%
Insulin Treatment
11%
Intima-Media Thickness
44%
Maturity Onset Diabetes of the Young
100%
Patient with Type 2 Diabetes
100%
Placebo
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
22%
Antidiabetic Agent
33%
Cardiovascular Disease
11%
Glycosylated Hemoglobin
11%
Hemoglobin A1c
55%
Insulin Analog
100%
Metformin
100%
Non Insulin Dependent Diabetes Mellitus
100%
Placebo
100%
Biochemistry, Genetics and Molecular Biology
Body Mass
50%
Glycated Hemoglobin
50%
Insulin Analog
100%
Sample Size
50%
Food Science
Glycosylated Hemoglobin
11%
Insulin
100%